REVIEW OF A NEW MULTIMODAL ANTIDEPRESSANT VORTIOXETINE

Oppa M1,2, Cesnekova D1,2, Nosalova G1,3, Ondrejka I2

Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital Martin
1Department of Pharmacology; 2Clinic of Psychiatry, Slovakia
3Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava

Abstract

Vortioxetine is a novel antidepressant with two mechanisms of action – direct effect on several serotonin receptors and serotonin re-uptake inhibition. It shows antidepressant, anxiolytic and cognitive effects during the treatment of major depressive disorder (MDD). The aim of this article was to summarize the use of vortioxetine in clinical studies and assess the efficacy and tolerability. Most of the studies reported a statistically significant efficacy for vortioxetine versus placebo. In addition, vortioxetine showed efficacy in patients with an inadequate response to selective serotonin re-uptake inhibitors (SSRI) or serotonin-noradrenaline re-uptake inhibitors (SNRI) monotherapy and improved cognitive function in patients with MDD. In these studies, vortioxetine was well tolerated – most common observed adverse effect was nausea – and it was not associated with clinically important changes in laboratory test results or vital signs. Vortioxetine showed a relatively low incidence of sexual dysfunction.

Key words: vortioxetine, depression, inadequate response, cognitive function, sexual dysfunction

INTRODUCTION

Major depressive disorder (MDD) is a disease with incidence rate of 4% [1] and lifetime prevalence in the range of 8% to 12% [2]. Depression affects the life quality and it has got impact to psychological variables like hope and meaning of life [3, 4]. According to the World Health Organization in year 2020 depression will become the second leading cause of disability.

Antidepressants are nowadays the main therapeutic option in depression treatment. Despite the large number of antidepressants, there are still limitations in their efficacy and tolerability, mainly in their affection of sexual and cognitive function and induction of weight gain, which can lead to worse therapeutic adherence and treatment interruptions. For that reason, the arrival of vortioxetine as a model of antidepressant with multimodal activity and safe profile generate strong interest.

The aim of this article is to summarize the use of vortioxetine from the results of manual searching of key publications with main focus on randomized, double-blind, placebo-controlled studies of vortioxetine that involve patients with an episode of MDD by DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition). Principal findings are summarised and assessed in discussion.

PHARMACOLOGY OF VORTIOXETINE

Vortioxetine (1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine;hydrobromide, Lu AA21004) shown in Figure 1 is a novel antidepressant with multimodal activity. It has two mechanisms of action – direct effect on several serotonin receptors (5-HT1A, 5-HT2A, 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist and 5-HT1A receptor agonist) and inhibition of serotonin transporter (SERT). It does not belong to the selective serotonin re-
uptake inhibitors (SSRI) because of their unimodal mechanism of action, but it is classified as a serotonin modulator and stimulator (SMS) along with vilazodone [5]. In vivo experimental studies have shown that vortioxetine increases extracellular concentration of serotonin in depression-related areas more than SSRIs, but it also increases the extracellular levels of noradrenaline, dopamine, acetylcholine and histamine [6].

Vortioxetine shows good bioavailability after oral administration (75%) with a $t_{\text{max}}$ of 7–8 hours and $t_{1/2}$ of 57 hours and it also shows a stable plasma concentrations in <2 weeks. Rate of binding to plasma proteins was 96%. Vortioxetine is extensively metabolized, primarily by oxidation and subsequent glucuronic acid conjugation. The P450 enzymes responsible for the metabolism include CYP2D6, CYP3A4/5, CYP2C9, CYP2C19, CYP2A6, CYP2C8, and CYP2B6 [7]. Vortioxetine shows no significant inhibition or induction of P450 enzymes, and is thus less prone to drug interactions, although dosage adjustment may be required when co-administered with bupropion (CYP2D6 inhibitor), or rifampicin (CYP inducer) [8].

![Chemical structure of vortioxetine.](image)

**EFFICACY OF VORTIOXETINE**

Efficacy of vortioxetine has been studied in 12 short-term (6, 8 or 12 weeks) clinical trials [9-20]. Eight of them were positive (seven for vortioxetine versus placebo, one for vortioxetine versus agomelatine as active comparator), three showed no significant differences versus placebo and one study failed because neither vortioxetine nor the duloxetine as active comparator were superior to placebo [9]. Six of the positive short-term studies showed positive results in the dosages 5–20 mg/day, but in two other positive studies vortioxetine was superior to placebo only in the highest dosage 20 mg/day. Patients typically respond to vortioxetine after two weeks of treatment, with the maximum response near the fourth week [1]. Outcomes are summarized in Table 1.

Vortioxetine showed statistically significant improvement versus placebo in the Rey Auditory Verbal Learning Test (RAVLT) and the Digit Symbol Substitution Test (DSST), which are cognitive neuropsychological tests of executive function, attention, speed of processing, verbal learning and memory in elderly patients with MDD [10]. In other short-term study with non-elderly adults with MDD, vortioxetine also showed significant difference versus placebo on the composite cognition score measured by DSST and RAVLT. Analyses indicated that the effect on cognitive performance was largely a direct treatment effect and not solely due to improvements in depressive symptoms [11]. Another study with MDD patients with an inadequate response to SSRI/SNRI monotherapy showed that vortioxetine was statistically superior to agomelatine as an active comparator in primary efficacy outcome [12].

Due to the character of the depression, long-term studies are necessary to demonstrate the effects of treatment over time and ability to prevent relapses. Two long-term efficacy studies of vortioxetine have been performed. The first one showed significant difference in time to relapse compared to placebo, with relapse rates of 13% for vortioxetine versus 26% for the placebo group [21]. The second study was an extension of a short-term study [9]. At the end of the treatment period, the mean MADRS (Montgomery and Asberg Depression Rating Scale) total score had improved by 8 points and the remission rate was 83% versus 42% in the lead-in study [22].
Table 1. Vortioxetine efficacy short-term randomized double-blind clinical studies in MDD patients.

<table>
<thead>
<tr>
<th>Author</th>
<th>Duration</th>
<th>FAS (n)</th>
<th>Placebo</th>
<th>Active comparator</th>
<th>Primary analysis</th>
<th>P-value</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alvarez et al., 2012</td>
<td>6 weeks</td>
<td>426</td>
<td>Yes</td>
<td>VLF</td>
<td>MADRS</td>
<td>p&lt;0.0001 (VOR vs. PBO), p&lt;0.0001 (VEN vs. PBO)</td>
<td>Positive¹</td>
</tr>
<tr>
<td>Baldwin et al., 2012</td>
<td>8 weeks</td>
<td>755</td>
<td>Yes</td>
<td>DLX</td>
<td>MADRS</td>
<td>NS (VOR vs. PBO), NS (DLX vs. PBO)</td>
<td>Failed²</td>
</tr>
<tr>
<td>Boulenger et al., 2014</td>
<td>8 weeks</td>
<td>604</td>
<td>Yes</td>
<td>DLX</td>
<td>MADRS-24</td>
<td>p&lt;0.0001 (VOR 15 + 20 mg vs. PBO), p&lt;0.0001 (DLX vs. PBO)</td>
<td>Positive¹</td>
</tr>
<tr>
<td>Häggström et al., 2013</td>
<td>12 weeks</td>
<td>493</td>
<td>No</td>
<td>AGO</td>
<td>MADRS-24</td>
<td>p&lt;0.001 (VOR vs. AGO)</td>
<td>Positive¹</td>
</tr>
<tr>
<td>Henisberg et al., 2012</td>
<td>8 weeks</td>
<td>556</td>
<td>Yes</td>
<td>No</td>
<td>HAMD-24</td>
<td>p&lt;0.001 (VOR 10 mg vs. PCB)</td>
<td>Positive¹</td>
</tr>
<tr>
<td>Jacobsen et al., 2013</td>
<td>8 weeks</td>
<td>385</td>
<td>Yes</td>
<td>No</td>
<td>MADRS</td>
<td>p=0.002 (VOR vs. PBO)</td>
<td>Positive¹</td>
</tr>
<tr>
<td>Jain et al., 2013</td>
<td>6 weeks</td>
<td>578</td>
<td>Yes</td>
<td>No</td>
<td>HAMD-24</td>
<td>NS (VOR vs. PBO)</td>
<td>Failed/negative⁴</td>
</tr>
<tr>
<td>Katona et al., 2012</td>
<td>8 weeks</td>
<td>448</td>
<td>Yes</td>
<td>DLX</td>
<td>HAMD-24</td>
<td>p=0.0011 (VOR vs. PBO), p=0.0001 (DLX vs. PBO)</td>
<td>Positive¹</td>
</tr>
<tr>
<td>Mahableshwarkar et al.,</td>
<td>8 weeks</td>
<td>434</td>
<td>Yes</td>
<td>No</td>
<td>MADRS</td>
<td>NS (VOR vs. PBO)</td>
<td>Failed/negative⁴</td>
</tr>
<tr>
<td>Mahableshwarkar et al.,</td>
<td>8 weeks</td>
<td>597</td>
<td>Yes</td>
<td>DLX</td>
<td>HAMD-24</td>
<td>NS (VOR vs. PBO), p&lt;0.005 (DLX vs. PBO)</td>
<td>Negative³</td>
</tr>
<tr>
<td>Mahableshwarkar et al.,</td>
<td>8 weeks</td>
<td>591</td>
<td>Yes</td>
<td>DLX</td>
<td>MADRS</td>
<td>p=0.023 (VOR vs. PBO), p&lt;0.001 (DLX vs. PBO)</td>
<td>Positive¹</td>
</tr>
<tr>
<td>McIntyre et al., 2014</td>
<td>8 weeks</td>
<td>591</td>
<td>Yes</td>
<td>No</td>
<td>MADRS</td>
<td>p&lt;0.001 (VOR vs. PBO)</td>
<td>Positive¹</td>
</tr>
</tbody>
</table>


¹Positive: The primary efficacy analysis was statistically significant. ²Failed: In the primary efficacy analysis, vortioxetine did not separate from placebo, nor did the active comparator. ³Negative: Vortioxetine did not but the active comparator did separate from placebo on the primary efficacy analysis. ⁴Failed/negative: Vortioxetine did not separate from placebo on the primary efficacy analysis, and no active reference was included in the study.
TOLERABILITY OF VORLXETINE

The safety data from the short-term as well as long-term clinical studies showed that the vortioxetine treatment is well tolerated. The incidence of adverse events was close to placebo level with the highest incidence of nausea mainly reported during the first weeks of dosing. Nausea was most often transient, with a median duration of 10 to 16 days. Clinical studies with vortioxetine have also shown that the incidence of sleep-related TEAEs (treatment emergent adverse events) like insomnia, hyposomnia or dysomnia was ranged from 2.0 to 5.1% for vortioxetine compared to 4.4% for placebo [23]. The studies also reported that the percentage of patients who develop sexual dysfunction is lower than for other antidepressants with serotoninergic activity. Rates of sexual dysfunction were low with vortioxetine in both short-term and long-term studies. The incidence of treatment-emergent sexual dysfunction in patients treated with vortioxetine ranged from 1.6 to 2.6% versus 4.5% with duloxetine. The review of vortioxetine conducted by the European Medicines Agency reported that the incidence of serious adverse events was generally low (<3%) [24].

DISCUSSION

Vortioxetine represents a new therapeutic option for the treatment of depression acutely and for relapse prevention. As a drug interacting with multiple receptors, it is associated with antidepressant, anxiolytic and cognitive effects during the treatment of MDD. Studies shown that vortioxetine was efficacious and well tolerated. Most of the studies reported a statistically significant efficacy for vortioxetine versus placebo. The effect of vortioxetine in patients with an inadequate response to SSRI or SNRI monotherapy can be explained by different mechanism of action. In addition, vortioxetine is associated with improved cognitive function in patients with MDD that is independent of improvement in depressive symptoms. The results from the long-term studies support the efficacy of vortioxetine in decreasing the risk of recurrence of depressive episodes after remission is achieved.

The most commonly observed adverse effect was nausea. Vortioxetine was not associated with clinically important changes in laboratory test results or vital signs [24]. It appears that vortioxetine have no effect on weight, which can lead to better therapeutic adherence than other antidepressants in which the association with weight gain has been established. Sexual dysfunction is known to be a potential symptom of depression, as well as a potential adverse event associated with certain drugs. Relatively low incidence of sexual dysfunction can be the advantage of vortioxetine opposite the other antidepressants with serotoninergic activity. But the mechanism of this remains to be studied in more details in the future studies.

REFERENCES


12. Häggström L, Nielsen RZ, Poulsen L, Danchenko N. A randomised, double blind, active controlled study of vortioxetine (10–20 mg/day) versus agomelatine (25–50 mg/day) in adults with Major Depressive Disorder with inadequate response to antidepressant treatment. Poster presented at: 26th Congress of the European College of Neuropsychopharmacology (ECNP); October 5-9, 2013; Barcelona, Spain.


Acknowledgement:
This work was supported by grants UK/90/2016 and UK 75/2016, and by the projects „Biomedical Center Martin”, ITMS code 262202220187, the project is co-financed from EU sources.

Received: April,26,2016
Accepted: June,27,2016